← FDA DRUG APPROVALS

FDA ANDA · ANDA202376

RABEPRAZOLE SODIUM

Sponsor: TORRENT

APPLICATION
ANDA202376
TYPE
ANDA
ORIGINAL APPROVAL
2013-11-08
LATEST ACTION
2024-04-23
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Prescription

Products

RABEPRAZOLE SODIUMPrescription
RABEPRAZOLE SODIUM 20MG · TABLET, DELAYED RELEASE · ORAL

Approval history

2024-04-23Labeling · Supplement 20 · standardAP
2022-09-02Labeling · Supplement 18 · standardAP
2021-09-14Labeling · Supplement 17 · standardAP
2018-11-30Labeling · Supplement 14 · standardAP
2018-11-30Labeling · Supplement 8 · standardAP
2018-11-30Labeling · Supplement 10 · standardAP
2018-11-30Labeling · Supplement 13 · standardAP
2015-04-02Labeling · Supplement 4 · standardAP
2015-04-02Labeling · Supplement 5 · standardAP
2013-11-08UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →